康达医谷（如图所示），坐落于上海张江科学城，是一个驱动生物技术创新的生命科学中心。
Concora Valley （pictured）, in Shanghai’s Zhangjiang Science City, is a life science hub driving biotech innovation.
通往中国生物医药繁荣的新门户
A NEW KIND OF GATEWAY TO CHINA’S BIOMEDICAL BOOM
中国生物技术产业正在蓬勃发展，这得益于日益增长的医疗健康需求、不断壮大的科研人才储备以及充满活力的风险投资体系。中国正日益成为全球生命科学领域的重要战略中心，尤其在创新药物研发与新型疗法领域表现突出。
China’s biotech sector is rapidly advancing, fuelled by an increasing demand for healthcare, a growing scientific talent pool, and a dynamic venture capital system. The nation is becoming an increasingly important strategic centre for global life science, particularly in innovative drug discovery and novel therapies.
Among China’s major cities, Shanghai is swiftly emerging as a global biotech hub, led by Zhangjiang Science City in the city’s Pudong region — known as ‘China’s Pharma Valley’. Covering nearly 95 square kilometres, it hosts the local operations of more than 1,700 biomedical companies, many clustered in an ‘International Medical Zone’, which offers access to a large patient base, accelerated clinical trials, and top-tier global research talent.
尽管这些优势显著，但如何高效整合人才与资源仍然是一大挑战——对全球生物医药公司而言尤其如此。“我们所见到的挑战包括基础设施支持、寻找合适的人才库、确保研发运营符合全球标准、应对复杂的监管要求以及适应本地生态系统，”生命科学企业家、康达源集团联合创始人高毅表示。
While these benefits are significant, efficiently integrating talent and resources remains a challenge — especially for global biomedical companies. “The hurdles we have seen include infrastructure support, identifying talent pools, ensuring R&D operations to meet global standards, navigating complex regulatory requirements, and adapting to the local ecosystem,” says Donald Gao, a life science entrepreneur and co-founder of Concora Group.
2021年，怀着更好地连接中国与全球生物技术生态系统的愿景，高毅与合作伙伴共同创立了康达源集团，并将其定义为一个生命科学创新与基础设施的“生态系统”。集团在张江科学城核心区拥有两大旗舰园区：康达源谷（Concora Place） 是一个聚焦研发的综合体；而康达医谷（Concora Valley） 则是一个规模更大、提供全方位服务的一体化园区。
In 2021, seeking to better connect the biotech ecosystems of China and the wider world, Gao and his partners established Concora Group, which they describe as a life science innovation and infrastructure ‘ecosystem’. It has two flagship campuses located in the heart of the Zhangjiang Science City: Concora Place is an R&D-focused complex, while Concora Valley is a larger, full-service campus.
康达源谷位于金科路2966号
从“Place” 到 “Valley”
FROM PLACE TO VALLEY
“对全球生物医药公司而言，在中国落地最大的挑战，往往在于能否获得强有力的整合性支持，以度过艰难的初创阶段，并在业务进入快速增长轨道后，依然能够高效配置资源，”高毅阐释道。
“For global biomedicine companies setting up, the biggest challenge is often finding strong, integrated support to get through the tough early stages, and managing resources effectively once growth takes off,” explains Gao.
The EverLab Innovation Center Laboratory was launched in 2024 at Concora Place to support early-stage drug discovery and innovative research. The collaborative lab spaces foster an open, innovative, and interactive ecosystem, and can be ready to move into within a single day. Units range from 100 to 300 square metres, with scalable options up to 3,000 square metres. Each lab is equipped with first-tier facilities and advanced instruments, professional supply chain support and on-site waste management to support high-level research.
EverLab创新中心实验室
“As companies scale into the clinical phase, they can move into Concora Valley,” he continues. The expansive campus spans nearly 72,000 square metres, comprising 18 standalone buildings and more than 3,000 square metres of pilot labs. It’s designed to support the full R&D lifecycle — from early-stage discovery to small-scale manufacturing production — with services covering planning, investment facilitation, administrative support and industry collaboration.
定制化服务
CUSTOMIZED SERVICES
硕迪生物便是在康达源谷（Concora Place）蓬勃发展的一家跨国临床阶段生物技术公司，其在南旧金山和上海均设有办事处。
One company that has thrived at Concora Place is Structure Therapeutics, a multinational clinical-stage biopharmaceutical firm with offices in South San Francisco and Shanghai.
该公司于2019年在张江科学园设立了上海分部，并于2023年通过与EverLab的合作扩大了其研发投入。
In 2019, it established Shanghai Structure at Zhangjiang Science Park, and expanded its R&D efforts in 2023 through a partnership with EverLab.
“我们欣赏张江充满活力的科学社区，康达源不仅提供了优质的实验室空间，更提供了一个开放、协作的创新生态系统，”硕迪生物的首席科学官、上海硕迪总经理林熹晨博士表示。
“We appreciate the vibrant Zhangjiang scientific community, and Concora provides not only premium lab space, but also an open, collaborative innovation ecosystem,” says Xichen Lin, chief scientific officer at Structure Therapeutics and general manager of its Shanghai site.
2025年，硕迪生物在康达源谷（Concora Place）进一步扩大了其规模。他们希望在满足高标准建设要求和紧张时间表的同时，适应其研发团队的发展。
In 2025, Lin and his team further expanded their presence at Concora Place. At that time, the company was looking to consolidate its R&D teams while meeting high construction standards and a tight timeline.
对此，康达源的团队提供了定制化的扩建服务、及时的技术支持和设施管理。
In response, Concora’s team offered customized expansion services, timely technical support and facility management.
The company is now tapping into the network of peers and experts in Concora Place to strengthen its expertise in China and forge partnerships that will accelerate the development of its pipeline.
点击阅读原文查看《Nature》专题报道《通往中国生物医药繁荣的新门户》
